imerge results: efficacy and disease-modifying activity of imetelstat in lr-mds after esa failure
Published 1 year ago • 597 plays • Length 2:40Download video MP4
Download video MP3
Similar videos
-
2:51
analysis of the imerge trial: the disease-modifying potential of imetelstat in lr-mds
-
1:25
the recent approval of imetelstat in lr-mds based on results of the imerge trial
-
1:44
imerge update: continuous transfusion independence & disease modification with imetelstat in lr-mds
-
4:32
recent advances in the treatment of lr-mds: commands and imerge trial data
-
2:44
latest updates in the treatment of lr-mds: commands and imerge trials
-
1:25
imerge subgroup study: imetelstat in patients with lr-mds previously exposed to esas
-
2:57
imetelstat for lr-mds: insights from the imerge trial
-
3:12
prolonged & continuous transfusion independence after imetelstat treatment in the imerge trial
-
5:30
commands: luspatercept vs epoetin alfa for anemia in esa-naive lr-mds
-
2:55
impactmf: imetelstat vs best available therapy in patients with myelofibrosis
-
4:28
gern stock gern geron coporation top stocks to buy in september
-
2:33
insights into the results and implications of the commands & imerge studies in lr-mds
-
3:47
current and emerging treatment options for lr-mds-associated anemia following esa failure
-
1:31
pevaz update: pevonedistat & azacitidine in r/r mds and mds/mpn after dnmti failure
-
1:52
advances in lr-mds and hr-mds in 2023 and beyond
-
2:05
does imetelstat increase the need for platelet transfusions & growth factors in pts with lr-mds?
-
2:07
ipps-m: incorporating genomic data into the ipps criteria for mds
-
1:30
the safety profile of imetelstat in myeloid malignancies
-
2:31
emerging treatment options for patients with esa-refractory mds: luspatercept & imetelstat
-
4:39
imetelstat shows promise in advanced myelofibrosis
-
1:03
insights into the cartitude-6 trial: rationale and design